HER2 Negative Breast CancerSymptoms, Doctors, Treatments, Advances & More
Learn About HER2 Negative Breast Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Christoph Thomssen practices practicing medicine in Halle, Germany. Mr. Thomssen is rated as an Elite expert by MediFind in the treatment of HER2 Negative Breast Cancer. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses HER2 Negative Breast Cancer, Breast Cancer, BRCA Positive Breast Cancer, Mastectomy, and Hormone Replacement Therapy (HRT).
UZ Leuven, Campus Gasthuisberg
Patrick Neven practices practicing medicine in Leuven, Belgium. Mr. Neven is rated as an Elite expert by MediFind in the treatment of HER2 Negative Breast Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Mastectomy, and Oophorectomy.
Emory Winship Cancer Institute
Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of HER2 Negative Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer. Dr. Kalinsky is currently accepting new patients.
Summary: The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as Signatera Genome) in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or contin...
Summary: The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria...